APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Human Chorionic Gonadotropin

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Recombinant Human Chorionic Gonadotropin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025180 pages

Choose your research edition.

Industry ResearchRecombinant Human Chorionic Gonadotropin Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Human Chorionic Gonadotropin Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Recombinant Human Chorionic Gonadotropin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Human Chorionic Gonadotropin Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Human Chorionic Gonadotropin Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Recombinant Human Chorionic Gonadotropin market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Recombinant Human Chorionic Gonadotropin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Human Chorionic Gonadotropin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Human Chorionic Gonadotropin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Recombinant Human Chorionic Gonadotropin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Recombinant Human Chorionic Gonadotropin include Merck, Ferring Pharmaceuticals, Wellona Pharma, Serum International Ltd, Schering Plough, Marvel Oceanic Private Limited, Facmed Pharmaceuticals and Bionomics Lifesciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Recombinant Human Chorionic Gonadotropin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Human Chorionic Gonadotropin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Human Chorionic Gonadotropin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Human Chorionic Gonadotropin market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant Human Chorionic Gonadotropin Segment by Company

Merck

Ferring Pharmaceuticals

Wellona Pharma

Serum International Ltd

Schering Plough

Marvel Oceanic Private Limited

Facmed Pharmaceuticals

Bionomics Lifesciences

Recombinant Human Chorionic Gonadotropin Segment by Type

Intramuscular Powder for Injection

Subcutaneous Solution for Injection

Recombinant Human Chorionic Gonadotropin Segment by Application

Female

Male

Recombinant Human Chorionic Gonadotropin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Human Chorionic Gonadotropin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Human Chorionic Gonadotropin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Human Chorionic Gonadotropin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Human Chorionic Gonadotropin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Recombinant Human Chorionic Gonadotropin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Recombinant Human Chorionic Gonadotropin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Recombinant Human Chorionic Gonadotropin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Recombinant Human Chorionic Gonadotropin Industry Trends Table 2. Recombinant Human Chorionic Gonadotropin Industry Drivers Table 3. Recombinant Human Chorionic Gonadotropin Industry Opportunities and Challenges Table 4. Recombinant Human Chorionic Gonadotropin Industry Restraints Table 5. Global Recombinant Human Chorionic Gonadotropin Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Recombinant Human Chorionic Gonadotropin Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Recombinant Human Chorionic Gonadotropin Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Recombinant Human Chorionic Gonadotropin Sales Market Share by Manufacturers Table 9. Global Recombinant Human Chorionic Gonadotropin Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Recombinant Human Chorionic Gonadotropin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Recombinant Human Chorionic Gonadotropin Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Recombinant Human Chorionic Gonadotropin Manufacturers, Product Type & Application Table 13. Global Recombinant Human Chorionic Gonadotropin Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Recombinant Human Chorionic Gonadotropin by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Intramuscular Powder for Injection Table 17. Major Manufacturers of Subcutaneous Solution for Injection Table 18. Global Recombinant Human Chorionic Gonadotropin Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Recombinant Human Chorionic Gonadotropin Sales by Type (2021-2026) & (k units) Table 20. Global Recombinant Human Chorionic Gonadotropin Sales by Type (2027-2032) & (k units) Table 21. Global Recombinant Human Chorionic Gonadotropin Sales Market Share by Type (2021-2026) Table 22. Global Recombinant Human Chorionic Gonadotropin Sales Market Share by Type (2027-2032) Table 23. Global Recombinant Human Chorionic Gonadotropin Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Recombinant Human Chorionic Gonadotropin Revenue by Type (2021-2026) & (k units) Table 25. Global Recombinant Human Chorionic Gonadotropin Revenue by Type (2027-2032) & (k units) Table 26. Global Recombinant Human Chorionic Gonadotropin Revenue Market Share by Type (2021-2026) Table 27. Global Recombinant Human Chorionic Gonadotropin Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Female Table 29. Major Manufacturers of Male Table 30. Global Recombinant Human Chorionic Gonadotropin Sales by Application 2021 VS 2025 VS 2032 (k units) Table 31. Global Recombinant Human Chorionic Gonadotropin Sales by Application (2021-2026) & (k units) Table 32. Global Recombinant Human Chorionic Gonadotropin Sales by Application (2027-2032) & (k units) Table 33. Global Recombinant Human Chorionic Gonadotropin Sales Market Share by Application (2021-2026) Table 34. Global Recombinant Human Chorionic Gonadotropin Sales Market Share by Application (2027-2032) Table 35. Global Recombinant Human Chorionic Gonadotropin Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Recombinant Human Chorionic Gonadotropin Revenue by Application (2021-2026) & (k units) Table 37. Global Recombinant Human Chorionic Gonadotropin Revenue by Application (2027-2032) & (k units) Table 38. Global Recombinant Human Chorionic Gonadotropin Revenue Market Share by Application (2021-2026) Table 39. Global Recombinant Human Chorionic Gonadotropin Revenue Market Share by Application (2027-2032) Table 40. Global Recombinant Human Chorionic Gonadotropin Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 41. Global Recombinant Human Chorionic Gonadotropin Sales by Region (2021-2026) & (k units) Table 42. Global Recombinant Human Chorionic Gonadotropin Sales Market Share by Region (2021-2026) Table 43. Global Recombinant Human Chorionic Gonadotropin Sales Forecasted by Region (2027-2032) & (k units) Table 44. Global Recombinant Human Chorionic Gonadotropin Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Recombinant Human Chorionic Gonadotropin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 46. North America Recombinant Human Chorionic Gonadotropin Sales by Country (2021-2026) & (k units) Table 47. North America Recombinant Human Chorionic Gonadotropin Sales by Country (2027-2032) & (k units) Table 48. Europe Recombinant Human Chorionic Gonadotropin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. Europe Recombinant Human Chorionic Gonadotropin Sales by Country (2021-2026) & (k units) Table 50. Europe Recombinant Human Chorionic Gonadotropin Sales by Country (2027-2032) & (k units) Table 51. Asia Pacific Recombinant Human Chorionic Gonadotropin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Asia Pacific Recombinant Human Chorionic Gonadotropin Sales by Country (2021-2026) & (k units) Table 53. Asia Pacific Recombinant Human Chorionic Gonadotropin Sales by Country (2027-2032) & (k units) Table 54. South America, Middle East and Africa Recombinant Human Chorionic Gonadotropin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. South America, Middle East and Africa Recombinant Human Chorionic Gonadotropin Sales by Country (2021-2026) & (k units) Table 56. South America, Middle East and Africa Recombinant Human Chorionic Gonadotropin Sales by Country (2027-2032) & (k units) Table 57. Global Recombinant Human Chorionic Gonadotropin Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Recombinant Human Chorionic Gonadotropin Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Recombinant Human Chorionic Gonadotropin Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Recombinant Human Chorionic Gonadotropin Revenue Market Share by Region (2021-2026) Table 61. Global Recombinant Human Chorionic Gonadotropin Revenue Market Share by Region (2027-2032) Table 62. Merck Company Information Table 63. Merck Business Overview Table 64. Merck Recombinant Human Chorionic Gonadotropin Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Merck Recombinant Human Chorionic Gonadotropin Product Portfolio Table 66. Merck Recent Development Table 67. Ferring Pharmaceuticals Company Information Table 68. Ferring Pharmaceuticals Business Overview Table 69. Ferring Pharmaceuticals Recombinant Human Chorionic Gonadotropin Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Ferring Pharmaceuticals Recombinant Human Chorionic Gonadotropin Product Portfolio Table 71. Ferring Pharmaceuticals Recent Development Table 72. Wellona Pharma Company Information Table 73. Wellona Pharma Business Overview Table 74. Wellona Pharma Recombinant Human Chorionic Gonadotropin Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Wellona Pharma Recombinant Human Chorionic Gonadotropin Product Portfolio Table 76. Wellona Pharma Recent Development Table 77. Serum International Ltd Company Information Table 78. Serum International Ltd Business Overview Table 79. Serum International Ltd Recombinant Human Chorionic Gonadotropin Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Serum International Ltd Recombinant Human Chorionic Gonadotropin Product Portfolio Table 81. Serum International Ltd Recent Development Table 82. Schering Plough Company Information Table 83. Schering Plough Business Overview Table 84. Schering Plough Recombinant Human Chorionic Gonadotropin Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Schering Plough Recombinant Human Chorionic Gonadotropin Product Portfolio Table 86. Schering Plough Recent Development Table 87. Marvel Oceanic Private Limited Company Information Table 88. Marvel Oceanic Private Limited Business Overview Table 89. Marvel Oceanic Private Limited Recombinant Human Chorionic Gonadotropin Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Marvel Oceanic Private Limited Recombinant Human Chorionic Gonadotropin Product Portfolio Table 91. Marvel Oceanic Private Limited Recent Development Table 92. Facmed Pharmaceuticals Company Information Table 93. Facmed Pharmaceuticals Business Overview Table 94. Facmed Pharmaceuticals Recombinant Human Chorionic Gonadotropin Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Facmed Pharmaceuticals Recombinant Human Chorionic Gonadotropin Product Portfolio Table 96. Facmed Pharmaceuticals Recent Development Table 97. Bionomics Lifesciences Company Information Table 98. Bionomics Lifesciences Business Overview Table 99. Bionomics Lifesciences Recombinant Human Chorionic Gonadotropin Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Bionomics Lifesciences Recombinant Human Chorionic Gonadotropin Product Portfolio Table 101. Bionomics Lifesciences Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Recombinant Human Chorionic Gonadotropin Distributors List Table 105. Recombinant Human Chorionic Gonadotropin Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Recombinant Human Chorionic Gonadotropin Product Image Figure 2. Global Recombinant Human Chorionic Gonadotropin Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Human Chorionic Gonadotropin Market Size (2021-2032) & (US$ Million) Figure 4. Global Recombinant Human Chorionic Gonadotropin Sales (2021-2032) & (k units) Figure 5. Global Recombinant Human Chorionic Gonadotropin Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Recombinant Human Chorionic Gonadotropin Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Intramuscular Powder for Injection Image Figure 9. Subcutaneous Solution for Injection Image Figure 10. Global Recombinant Human Chorionic Gonadotropin Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Recombinant Human Chorionic Gonadotropin Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Recombinant Human Chorionic Gonadotropin Sales Market Share by Type (2021-2032) Figure 13. Global Recombinant Human Chorionic Gonadotropin Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Recombinant Human Chorionic Gonadotropin Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Recombinant Human Chorionic Gonadotropin Revenue Market Share by Type (2021-2032) Figure 16. Female Image Figure 17. Male Image Figure 18. Global Recombinant Human Chorionic Gonadotropin Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Recombinant Human Chorionic Gonadotropin Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Recombinant Human Chorionic Gonadotropin Sales Market Share by Application (2021-2032) Figure 21. Global Recombinant Human Chorionic Gonadotropin Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Recombinant Human Chorionic Gonadotropin Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Recombinant Human Chorionic Gonadotropin Revenue Market Share by Application (2021-2032) Figure 24. North America Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 25. North America Recombinant Human Chorionic Gonadotropin Sales Market Share by Country (2021-2032) Figure 26. U.S. Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 27. Canada Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 28. Mexico Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 29. Europe Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Recombinant Human Chorionic Gonadotropin Sales Market Share by Country (2021-2032) Figure 31. Germany Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 32. France Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 33. U.K. Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 34. Italy Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 35. Netherlands Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 36. Asia Pacific Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Recombinant Human Chorionic Gonadotropin Sales Market Share by Country (2021-2032) Figure 38. China Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 39. Japan Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 40. South Korea Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 41. Southeast Asia Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 42. India Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 43. Australia Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 44. South America, Middle East and Africa Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Recombinant Human Chorionic Gonadotropin Sales Market Share by Country (2021-2032) Figure 46. Brazil Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 47. South Africa Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 48. Saudi Arabia Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 49. Turkey Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 50. Argentina Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 51. UAE Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 52. Egypt Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 53. Chile Recombinant Human Chorionic Gonadotropin Sales and Growth Rate (2021-2032) & (k units) Figure 54. Global Recombinant Human Chorionic Gonadotropin Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Recombinant Human Chorionic Gonadotropin Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Recombinant Human Chorionic Gonadotropin Revenue (2021-2032) & (US$ Million) Figure 57. North America Recombinant Human Chorionic Gonadotropin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Recombinant Human Chorionic Gonadotropin Revenue (2021-2032) & (US$ Million) Figure 59. Europe Recombinant Human Chorionic Gonadotropin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Recombinant Human Chorionic Gonadotropin Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Recombinant Human Chorionic Gonadotropin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Recombinant Human Chorionic Gonadotropin Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Recombinant Human Chorionic Gonadotropin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Recombinant Human Chorionic Gonadotropin Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Recombinant Human Chorionic Gonadotropin Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Intramuscular Powder for Injection
  • Subcutaneous Solution for Injection
Applications
  • Female
  • Male
Companies covered
  • Merck
  • Ferring Pharmaceuticals
  • Wellona Pharma
  • Serum International Ltd
  • Schering Plough
  • Marvel Oceanic Private Limited
  • Facmed Pharmaceuticals
  • Bionomics Lifesciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Recombinant Human Chorionic Gonadotropin Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Recombinant Human Chorionic Gonadotropin Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Recombinant Human Chorionic Gonadotropin Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Recombinant Human Chorionic Gonadotropin Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Recombinant Human Chorionic Gonadotropin Market Dynamics
  1. 2.1 Recombinant Human Chorionic Gonadotropin Industry Trends
  2. 2.2 Recombinant Human Chorionic Gonadotropin Industry Drivers
  3. 2.3 Recombinant Human Chorionic Gonadotropin Industry Opportunities and Challenges
  4. 2.4 Recombinant Human Chorionic Gonadotropin Industry Restraints
3 Recombinant Human Chorionic Gonadotropin Market by Manufacturers
  1. 3.1 Global Recombinant Human Chorionic Gonadotropin Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Recombinant Human Chorionic Gonadotropin Sales by Manufacturers (2021-2026)
  3. 3.3 Global Recombinant Human Chorionic Gonadotropin Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Recombinant Human Chorionic Gonadotropin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Recombinant Human Chorionic Gonadotropin Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Recombinant Human Chorionic Gonadotropin Manufacturers, Product Type & Application
  7. 3.7 Global Recombinant Human Chorionic Gonadotropin Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Recombinant Human Chorionic Gonadotropin Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Recombinant Human Chorionic Gonadotropin Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Recombinant Human Chorionic Gonadotropin Tier 1, Tier 2, and Tier 3
4 Recombinant Human Chorionic Gonadotropin Market by Type
  1. 4.1 Recombinant Human Chorionic Gonadotropin Type Introduction
  2. 4.1.1 Intramuscular Powder for Injection
  3. 4.1.2 Subcutaneous Solution for Injection
  4. 4.2 Global Recombinant Human Chorionic Gonadotropin Sales by Type
  5. 4.2.1 Global Recombinant Human Chorionic Gonadotropin Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Recombinant Human Chorionic Gonadotropin Sales by Type (2021-2032)
  7. 4.2.3 Global Recombinant Human Chorionic Gonadotropin Sales Market Share by Type (2021-2032)
  8. 4.3 Global Recombinant Human Chorionic Gonadotropin Revenue by Type
  9. 4.3.1 Global Recombinant Human Chorionic Gonadotropin Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Recombinant Human Chorionic Gonadotropin Revenue by Type (2021-2032)
  11. 4.3.3 Global Recombinant Human Chorionic Gonadotropin Revenue Market Share by Type (2021-2032)
5 Recombinant Human Chorionic Gonadotropin Market by Application
  1. 5.1 Recombinant Human Chorionic Gonadotropin Application Introduction
  2. 5.1.1 Female
  3. 5.1.2 Male
  4. 5.2 Global Recombinant Human Chorionic Gonadotropin Sales by Application
  5. 5.2.1 Global Recombinant Human Chorionic Gonadotropin Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Recombinant Human Chorionic Gonadotropin Sales by Application (2021-2032)
  7. 5.2.3 Global Recombinant Human Chorionic Gonadotropin Sales Market Share by Application (2021-2032)
  8. 5.3 Global Recombinant Human Chorionic Gonadotropin Revenue by Application
  9. 5.3.1 Global Recombinant Human Chorionic Gonadotropin Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Recombinant Human Chorionic Gonadotropin Revenue by Application (2021-2032)
  11. 5.3.3 Global Recombinant Human Chorionic Gonadotropin Revenue Market Share by Application (2021-2032)
6 Global Recombinant Human Chorionic Gonadotropin Sales by Region
  1. 6.1 Global Recombinant Human Chorionic Gonadotropin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Human Chorionic Gonadotropin Sales by Region (2021-2032)
  3. 6.2.1 Global Recombinant Human Chorionic Gonadotropin Sales by Region (2021-2026)
  4. 6.2.2 Global Recombinant Human Chorionic Gonadotropin Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Recombinant Human Chorionic Gonadotropin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Recombinant Human Chorionic Gonadotropin Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Recombinant Human Chorionic Gonadotropin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Recombinant Human Chorionic Gonadotropin Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Recombinant Human Chorionic Gonadotropin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Recombinant Human Chorionic Gonadotropin Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Recombinant Human Chorionic Gonadotropin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Recombinant Human Chorionic Gonadotropin Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Recombinant Human Chorionic Gonadotropin Revenue by Region
  1. 7.1 Global Recombinant Human Chorionic Gonadotropin Revenue by Region
  2. 7.1.1 Global Recombinant Human Chorionic Gonadotropin Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Recombinant Human Chorionic Gonadotropin Revenue by Region (2021-2026)
  4. 7.1.3 Global Recombinant Human Chorionic Gonadotropin Revenue by Region (2027-2032)
  5. 7.1.4 Global Recombinant Human Chorionic Gonadotropin Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Recombinant Human Chorionic Gonadotropin Revenue (2021-2032)
  8. 7.2.2 North America Recombinant Human Chorionic Gonadotropin Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Recombinant Human Chorionic Gonadotropin Revenue (2021-2032)
  11. 7.3.2 Europe Recombinant Human Chorionic Gonadotropin Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Recombinant Human Chorionic Gonadotropin Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Recombinant Human Chorionic Gonadotropin Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Recombinant Human Chorionic Gonadotropin Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Recombinant Human Chorionic Gonadotropin Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Recombinant Human Chorionic Gonadotropin Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck Recombinant Human Chorionic Gonadotropin Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Ferring Pharmaceuticals
  8. 8.2.1 Ferring Pharmaceuticals Company Information
  9. 8.2.2 Ferring Pharmaceuticals Business Overview
  10. 8.2.3 Ferring Pharmaceuticals Recombinant Human Chorionic Gonadotropin Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ferring Pharmaceuticals Recombinant Human Chorionic Gonadotropin Product Portfolio
  12. 8.2.5 Ferring Pharmaceuticals Recent Developments
  13. 8.3 Wellona Pharma
  14. 8.3.1 Wellona Pharma Company Information
  15. 8.3.2 Wellona Pharma Business Overview
  16. 8.3.3 Wellona Pharma Recombinant Human Chorionic Gonadotropin Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Wellona Pharma Recombinant Human Chorionic Gonadotropin Product Portfolio
  18. 8.3.5 Wellona Pharma Recent Developments
  19. 8.4 Serum International Ltd
  20. 8.4.1 Serum International Ltd Company Information
  21. 8.4.2 Serum International Ltd Business Overview
  22. 8.4.3 Serum International Ltd Recombinant Human Chorionic Gonadotropin Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Serum International Ltd Recombinant Human Chorionic Gonadotropin Product Portfolio
  24. 8.4.5 Serum International Ltd Recent Developments
  25. 8.5 Schering Plough
  26. 8.5.1 Schering Plough Company Information
  27. 8.5.2 Schering Plough Business Overview
  28. 8.5.3 Schering Plough Recombinant Human Chorionic Gonadotropin Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Schering Plough Recombinant Human Chorionic Gonadotropin Product Portfolio
  30. 8.5.5 Schering Plough Recent Developments
  31. 8.6 Marvel Oceanic Private Limited
  32. 8.6.1 Marvel Oceanic Private Limited Company Information
  33. 8.6.2 Marvel Oceanic Private Limited Business Overview
  34. 8.6.3 Marvel Oceanic Private Limited Recombinant Human Chorionic Gonadotropin Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Marvel Oceanic Private Limited Recombinant Human Chorionic Gonadotropin Product Portfolio
  36. 8.6.5 Marvel Oceanic Private Limited Recent Developments
  37. 8.7 Facmed Pharmaceuticals
  38. 8.7.1 Facmed Pharmaceuticals Company Information
  39. 8.7.2 Facmed Pharmaceuticals Business Overview
  40. 8.7.3 Facmed Pharmaceuticals Recombinant Human Chorionic Gonadotropin Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Facmed Pharmaceuticals Recombinant Human Chorionic Gonadotropin Product Portfolio
  42. 8.7.5 Facmed Pharmaceuticals Recent Developments
  43. 8.8 Bionomics Lifesciences
  44. 8.8.1 Bionomics Lifesciences Company Information
  45. 8.8.2 Bionomics Lifesciences Business Overview
  46. 8.8.3 Bionomics Lifesciences Recombinant Human Chorionic Gonadotropin Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bionomics Lifesciences Recombinant Human Chorionic Gonadotropin Product Portfolio
  48. 8.8.5 Bionomics Lifesciences Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Recombinant Human Chorionic Gonadotropin Value Chain Analysis
  2. 9.1.1 Recombinant Human Chorionic Gonadotropin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Recombinant Human Chorionic Gonadotropin Production Mode & Process
  6. 9.2 Recombinant Human Chorionic Gonadotropin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Recombinant Human Chorionic Gonadotropin Distributors
  9. 9.2.3 Recombinant Human Chorionic Gonadotropin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst